MetaCap

Cardiol Therapeutics (CRDL) vs Invivyd (IVVD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Invivyd (IVVD) over the past year, losing 11.3% versus a loss of 83.5%. Over five years, CRDL leads with a -60.1% price change compared with -98.4% for IVVD. Invivyd is the larger company by market cap ($122.0 million vs $110.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%IVVD-83.49%
+146%+26%-94%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%IVVD-97.94%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus IVVD key metrics
MetricCRDLIVVD
Share price$0.8626$0.4127
Market cap$110.14M$122.01M
1-day change-2.28%-7.45%
YTD return-9.58%-83.29%
1-year return-11.35%-83.49%
5-year return-60.06%-98.36%
EPS (TTM)$-0.24$-0.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$53.43M
Revenue growth (YoY)—+110.47%
Net income (latest FY)—$-52.49M
Operating margin—-103.99%
Net margin—-98.25%
52-week high$2.34$3.01
52-week low$0.8417$0.4127
Distance from 52-week high-63.14%-86.29%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+874.96%+2323.07%
Average volume1.20M5.20M
Shares outstanding127.69M295.63M
Employees18122
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed IVVD by 72.1 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Invivyd

IVVD stock →

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees

CRDL vs IVVD FAQ

Which is bigger, Cardiol Therapeutics or Invivyd?

Invivyd (IVVD) is larger, with a market capitalization of $122.01M compared with $110.14M for Cardiol Therapeutics (CRDL).

Which stock has performed better over the past year, CRDL or IVVD?

CRDL returned -11.35% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Invivyd in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons